Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...

On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on ‘Squawk Box’ to discuss the potential challenges and opportunities the pharmaceutical industry may face under the ...

Stäubli Robotics in collaboration with a prominent pharmaceutical company has developed a mobile robot for use in Grade A/B/C/D cleanrooms. A cross-functional team ...

Innocan Pharma Ltd. Each Warrant is exercisable into one Common Share at a price of CAD$0.26 for a period of four (4) years from the date of issuance. Innocan intends to use the proceeds of the ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

Kennedy Jr. — who also happens to now run the Department of Health and Human Services — have castigated the pharma sector for its all-too-cozy relationship with the FDA, including its penchant ...

However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some analysts project that Rezdiffra could generate peak annual sales of close to $3.5 ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...